PMID: 9448552Feb 4, 1998Paper

A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group

Archives of Internal Medicine
H J SchwartzJ Lancaster

Abstract

Zileuton, a leukotriene pathway inhibitor, was compared with slowly absorbed theophylline in a randomized, double-blind study of patients with chronic asthma. The primary efficacy measure was improvement in forced expiratory volume in 1 second (FEV1). Eligibility criteria included FEV1 of 40% to 80% of predicted, documented reversibility of airway disease, and age 18 to 60 years. Initially, the theophylline dosage was titrated to achieve trough concentrations of 8 to 15 micrograms/mL. After washout and 1-week placebo lead-in, patients were randomly assigned to 13 weeks of the appropriate theophylline dose or zileuton, 400 or 600 mg 4 times daily. The FEV1 was measured before the morning dose at 2-week intervals and serially after the dose on days 36 and 92. Patients kept daily diaries of asthma symptoms, beta-agonist usage, and peak expiratory flow rate; on days 36 and 92, they completed quality-of-life questionnaires. Of 471 eligible patients at 38 centers, 377 were randomly assigned to the study; 313 completed the study. On first-dose administration, all groups showed 11% to 13% improvement in FEV1 within 30 minutes. Patients who received zileuton, 400 mg, had significantly greater improvement at several points than did theop...Continue Reading

Citations

Sep 9, 1999·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·L García-Marcos, A Schuster
Jun 3, 2005·The Journal of Clinical Investigation·Andre BaficaJulio Aliberti
Aug 7, 1999·Clinical Reviews in Allergy & Immunology·S L Spector
Jun 1, 2000·Indian Journal of Pediatrics·G Gupta
Feb 29, 2000·The Journal of the American Osteopathic Association·S M Gawchik, C L Saccar
Mar 27, 2001·Family Practice·M EcclesUNKNOWN North of England Asthma Guideline Development Group
May 5, 2001·Expert Opinion on Pharmacotherapy·L García-Marcos, A Schuster
Feb 28, 2001·Expert Opinion on Investigational Drugs·T C Theoharides, G R Sant
Mar 31, 2007·International Journal of Clinical Practice·W BergerC B Cairns
Feb 24, 2001·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·M J Massanari
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S D Crowther, P J Rees
Dec 16, 1998·Respiratory Medicine·S J Lane
Apr 24, 2004·The Cochrane Database of Systematic Reviews·F DucharmeR Kakuma
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Parameswaran NairBrian H Rowe
Feb 27, 2001·Current Opinion in Pulmonary Medicine·J F Donohue, J A Ohar
Oct 19, 2004·The Nurse Practitioner·Kevin R MurphyNancy L Sarver
Nov 26, 2020·International Forum of Allergy & Rhinology·Richard R OrlandiBing Zhou
Feb 26, 2008·European Journal of Pharmacology·Ben S ZweifelJaime L Masferrer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.